Abstract Number: 0956 • ACR Convergence 2021
Racial Disparities in Renal Outcomes over Time Among Hospitalized Children with SLE and Effects of Hospital Minority Composition
Background/Purpose: Racial and ethnic minorities are disproportionately affected by pediatric-onset SLE and have worse outcomes compared to their white counterparts. With ongoing advances in pediatric…Abstract Number: 0972 • ACR Convergence 2021
Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells Which Enhances TGF-β1 Activation and Promotes Tissue Fibrosis in Lupus Nephritis
Background/Purpose: Enhanced expression of transforming growth factor-beta (TGF-β) in the kidneys of patients with lupus nephritis (LN) can lead to progressive fibrosis, resulting in end-organ…Abstract Number: 1270 • ACR Convergence 2021
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), occurring in approximately 40% of SLE patients (pts) and often resulting in…Abstract Number: 1284 • ACR Convergence 2021
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…Abstract Number: 1482 • ACR Convergence 2021
LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
Background/Purpose: LN is a severe consequence of SLE and there is a huge unmet need for discovery of urine protein biomarkers that provide non-invasive surrogates…Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…Abstract Number: 1757 • ACR Convergence 2021
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus…Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…Abstract Number: 0327 • ACR Convergence 2021
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…Abstract Number: 0649 • ACR Convergence 2020
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report
Background/Purpose: Gout’s high prevalence in kidney transplant (KT) recipients has been associated with heavy residual urate burden, decreased urate excretion related to reduced renal function,…Abstract Number: 0682 • ACR Convergence 2020
Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout
Background/Purpose: To understand the role of inflammatory cytokines and oxidative stress biomarkers in the renal disease in people with gout. We hypothesized that higher gout…Abstract Number: 0686 • ACR Convergence 2020
Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort
Background/Purpose: Gout is associated with chronic kidney disease, but how the kidney function evolves when gout is treated with urate lowering therapy (ULT) is still…Abstract Number: 0856 • ACR Convergence 2020
Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels
Background/Purpose: Hydroxychloroquine (HCQ) dosing is reduced in those with renal insufficiency according to guidelines (Marmor MF, et al. Ophthalmology 2016;123:1386–94) as it is partially cleared…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »